Streptozotocin, a new antitumor agent with diabetogenie properties, was administered to a patient with functioning islet cell carcinoma. Tumor regression occurred and hypoglycemic symptoms disappeared. Drug-related renal and hepatic toxicity is discussed.
This content is only available via PDF.
Copyright © 1969 by the American Diabetes Association
1969
